Physician profile
Christopher Bailey
NPI 1275602070
$8,356.07
in general payments reported to CMS, 2019-2025
42 companies · $4,599 in 2025
The $4,599 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $536 · 2021: $526 · 2022: $729 · 2023: $579 · 2024: $525 · 2025: $4,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,638 · Food and Beverage: $2,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,637.50 |
| Food and Beverage | $2,066.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $4,002.77 | 2022-2025 | Sublocade |
| Abbvie INC. | $1,323.56 | 2020-2025 | Qulipta, Vraylar, Linzess |
| Novo Nordisk INC | $292.75 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $267.17 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $229.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $184.46 | 2019-2020 | |
| Pfizer INC. | $180.88 | 2019-2025 | |
| Lilly USA, LLC | $171.40 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $162.51 | 2019-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $136.05 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Gilead Sciences, INC. | $126.71 | 2024-2025 | Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.26 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $117.00 | 2019-2025 | Eliquis, Cobenfy |
| Novartis Pharmaceuticals Corporation | $100.72 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.88 | 2022-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.